Observational studyJournal of the American Heart Association2025
Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy With and Without Spontaneous Lobar Hemorrhage.
Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04204642 (SEarchiNg biomarkErs Cerebral Amyloid Angiopathy), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA
Who cites it
2 citing papers in PubMed.
- Cerebrospinal Fluid Amyloid-β Biomarkers Predict Future Hemorrhage in Patients with Cerebral Amyloid Angiopathy.Annals of neurology · 2026Article
- Profiles of blood-brain barrier and neurodegeneration markers in cerebrospinal fluid of patients with cerebral amyloid angiopathy.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral amyloid angiopathy (CAA) typically presents as spontaneous lobar intracerebral hemorrhage (ICH) or cognitive impairment. While the Boston criteria 2.0 aid CAA diagnosis in ICH, detecting nonhemorrhagic cases remains challenging. Cerebrospinal fluid (CSF) biomarkers may offer valuable diagnostic support. This study aimed to evaluate CSF Aβ40, Aβ42, total-τ, phosphorylated-τ, Aβ42/Aβ40, and phosphorylated-τ/Aβ42 in patients with CAA with and without symptomatic ICH.
methodsThis prospective observational study recruited patients with CAA from the cerebrovascular clinic of Fondazione IRCCS Istituto Neurologico Carlo Besta (Milan, Italy) from January 2021 to June 2024. Patients underwent T2*-weighted magnetic resonance imaging and lumbar puncture, with CSF biomarkers measured via Lumipulse. Participants were grouped into CAA-ICH+ (prior symptomatic lobar ICH) and CAA-ICH-.
resultsFifty-four patients were included: 35 CAA-ICH+ (37.1% women) and 19 CAA-ICH- (52.4% men). Groups were similar in mean age at lumbar puncture (63.8 versus 67.9 years) and cognitive impairment prevalence (57.1% versus 47.4%). Median CSF Aβ40 level was significantly lower in CAA-ICH+ than in CAA-ICH- (4355 versus 6507 pg/mL,
conclusionsCSF Aβ40 is significantly lower in patients with CAA with prior ICH. Amyloid dysregulation in CAA may follow distinct pathological trajectories depending on previous ICH. CSF Aβ40 shows promise as a biomarker for CAA and merits further studies to explore its prognostic value in disease progression. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04204642.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.